PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 11 | Issue - 10 | October - 2022 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

201	urnal or P	OR	IGINAL RESEARCH PAPER	Dermatology		
Indian	PARIPET.	A CI DER OF	INICAL STUDY OF GERIATRIC MATOSES IN TERTIARY CARE HOSPITAL GUJARAT	KEY WORDS: geriatric, dermatoses, Xerosis		
Dr Dharaben Jaiminkumar Patel			Assistant Professor.			
Dr Dhwaniben Ranchhodbhai Makwana		n li	Senior Resident.			
Dr Nehabahen Trikambhai Solanki		n	* Corresponding Author			
Dr. Kirti Parmar		nar	Professor & HOD, Skin OPD, Dr. M. K. Shah medical college and research centre, Ahmedabad:-382424.			
	Background: Ageing is a complex multi-factorial phenomenon in which progressive intrinsic changes in the ski combine synergistically with cumulative environmental insults to produce both structural and functional disturbance Objectives: (1) To estimate prevalence of physiological senile changes among participants (2) To estimate prevalence of various symptoms and diseases including cutaneous tumours among participants (3) To find out prevalence of various			ssive intrinsic changes in the skin actural and functional disturbances. ticipants (2) To estimate prevalence (3) To find out prevalence of various		

co-morbidities among participants. **Method:** A cross sectional observational study was conducted involving 638 elderly participants using purposive sampling method at tertiary care centre of Gujarat. A proforma having sections related to

demographic profile, clinical history, cutaneous and systemic examination and laboratory findings were used for data collection. **Results:** About 72% participants were male. About 58% of participants were of 60-69 years. Common geriatric changes were Canities (91%), Wrinkling (86%) and Xerosis (82%). Generalized Pruritus was seen in 68%. Fungal, Bacterial, Viral infections and Parasitic infestation were seen in 28%, 26%, 12% and 7% of participants..Eczematous conditions were seen in almost 26%. Papulo-squamous disorder, Cutaneous adverse drug reactions, Pigmentary disorders, Vesicobullous disorder and Autoimmune Connective tissue disorder were less prevalent (<5%). Co-morbidities like Hypertension, Diabetes, Ischemic heart diseases and Hypothyroidism were seen in 13%, 12%, 5% and 4% participants respectively. Commonest benign tumour was cherry Angioma (68%) while malignant tumor was rare (<1%). **Conclusion:** Physiological changes such as Xerosis and Senile pruritus alone can significantly lead to distress to the elderly patients.By integrating this knowledge in health care facilities we can improve

ABSTRACT

INTRODUCTION:

Life expectancy is continuously increasing globally over the years ^[1]. In India also, life expectancy is consistently showing an upward trend with rise of 29 points from the year 1960 (41 years) to year 2020 (70 years) $^{[2]}$. Ageing is a complex multifactorial phenomenon in which progressive intrinsic changes in the skin combine synergistically with cumulative environmental insults to produce both structural and functional disturbances ^{[3].} United Nations defines elderly as those of more than 60 years of age [4]. Ageing gives rise to various trivial dermatological manifestations such as pruritus, xerosis,etc ^{[5].} However, many dermatological conditions like skin malignancy can lead to significant morbidity and impairment of quality of life ^{[6].} This study was conducted with the intention of knowing various dermatological conditions of the elderly population and their prevalence in Western India which will help health systems to be better acquainted and prepared for the rising dermatological health problems of the elderly.

the quality of life of older age population.

MATERIALS AND METHODOLOGY:

This study is a Cross sectional Observational study carried out in a tertiary care centre in Gujarat within duration of 12 months from September 2020 to August 2021. By purposive Sampling method, we have included 638 subjects over 60 years of age in our study.

Inclusion Criteria:

All patients aged 60 years and above attending the outpatient as well as indoor patient department of study centre who are www.worldwidejournals.com willing to give informed written consent for the study.

Exclusion Criteria:

Patients not willing to participate in the study.

All patients above age 60 years were included in this study. Written informed consent was taken from all the patients. Detailed demographic data was collected as per predesigned proforma. All patients were subjected to detailed clinical evaluation including clinical history of symptoms, thorough cutaneous and systemic examination and a battery of laboratory investigations according to clinical symptoms. Investigations like CBC, liver function test, renal function test, random blood sugar done for all cases and specific tests such as thyroid function tests, serum lipid profile, radiological investigations like chest X Ray, USG (abdomen), microbiological investigations like KOH mount, Tzanck smear, slit skin smear for evaluation of acid fast bacilli, histopathological examination of skin biopsy done for all relevant cases or in those the diagnoses could not be arrived clinically. All the data collected by author and co-authors was recorded in MS Excel version 10. Data was tabulated and analyzed statistically using SPSS version 2.0. Ethical Review was done at Institutional ethical committee and the study was permitted by the same.

RESULTS:

Table 1: Demographic Profile Of Participants

Age group (years)	Male (%)	Female (%)	Total (%)
60-69	231(62)	142(38%)	373 (58.46%)

PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 11 | Issue - 10 | October - 2022 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

Total

29

15

44

70-79	199(88.4%)	26(11.6%)	225 (35.27%)		
80-89	28(75.7%)	9(24.3%)	37 (5.8%)		
>90	2(67.7%)	1(33.3%)	3 (0.47%)		
Total 460(72%) 178(28%) 638 (100%)					
\mathbf{H}_{1}					

Table 1 showed that we had 72% of male and 28% female patients in our study with male to female ratio of 2.57:1. Most commonly affected age group was 60-69 years (58.5%) followed by 70-79 years (35%).

Table 2: Distribution Of Senile Physiological Changes Amongst Participants (n=638)

Sr No	Senile Changes	Frequency	Percentage
1	Xerosis	523	82%
2	Wrinkling	548	86%
3	Idiopathic Guttate	338	53%
	Hypomelanosis		
4	Senile comedones	44	7%
5	Senile lentigenes	82	13%
6	Senile purpura	70	11%
7	Canities	580	91%
8	Cherry angioma	430	67%

As seen from table 2 that most common senile (physiological) dermatological change was canities which was seen in 9 out of every 10 participants followed by wrinkling (86%) and xerosis (82%). Cherry angioma was seen in about 70% of participants while about half of participants (53%) were having idiopathic guttate hypomelanosis.

Table 3: Distribution Of Diseases Amongst Participants

Sr. No	Disease		no. of male patients (n=460)	No of female patients (n= 178)	Total (n=638)
1.	Generalised pruritus		303	130	433
			(65.87%)	(73%)	(67.87%)
2.	Fungal	Dermatophytos	10	26	36
	infection	es	(2.17%)	(14.6%)	(5.64%)
		Onychomycosis	37	20	57
			(8.04%)	(11.23%)	(8.93%)
		Candidiasis	69	18	87
			(15.00%)	(10.11%)	(13.64%)
		Total	116	64 (36%)	180
			(25.21%)		(28.21%)
3.	Bacterial	Furunculosis	73	19	92
	infections		(15.86%)	(10.67%)	(14.42%)
		Folliculitis	42	10	52
			(9.13%)	(5.63%)	(8.20%)
		Erythrasma	09	03	12
			(1.95%)	(1.68%)	(1.9%)
		Pitted	04	06	10
		keratolysis	(0.86%)	(3.3%)	(1.57%)
		Leprosy	01	00	01
			(0.22%)		(0.16%)
		Total	129	38	167
			(28.04%)	(21.34%)	(26.20%)
4.	Viral	Herpes zoster	31	13	44
	infection		(6.73%)	(7.30%)	(6.9%)
		Herpes simplex	09	02	11
			(1.95%)	(1.12%)	(1.72%)
		Wart	14	04	18
			(3.04%)	(2.25%)	(2.82%)
		Viral	05	01	06
		exanthema	(1.08%)	(0.56%)	(0.94%)
		Total	59	20	79
			(14.53%)	(11.23%)	(12.38%)
5.	Parasitic	Scabies	27	11	38
	infestatio		(5.86%)	(6.18%)	(5.96%)
	n	Pediculosis	02	04	06
			(0.43%)	(2.25%)	(0.94%)

6. Eczema Allergic contact 32 24 56 dermatitis (6.95%) (13.48%) (8.78%) Asteoata (8.47%) (10.11%) (8.93%) Irritant contact (3 01 04 dermatitis (0.66%) (0.63%) Numular 11 05 16 eczema (2.31%) (2.81%) (2.90%) Hyperkeratotic (2.61%) (3.93%) (2.98%) Air borne 05 00 05 contact (1.09%) (0.56%) (1.25%) Air borne 05 01 08 contact (1.09%) (1.68%) (2.50%) Air borne 05 01 05 contact (1.98%) (1.68%) (2.50%) quarna (2.83%) (1.68%) (2.50%) quarna (2.83%) (1.68%) (0.94%) quarna (2.83%) (1.68%) (0.94%) quarna (2.83%) (1.68%) (0.94%) quarna (2.83%) (1.68%) (0.94%) quarna (1.94%) (3.60%) (1.41%) quarna (1.94%) (3.64%) (3.45%)				(6.30%)	(8.43%)	(6.90%)
8. Acrossssssssssssssssssssssssssssssssssss	6.	Eczema	Allergic contact	32	24	56
Recorana 99 18 57 eczema (8.47%) (10.11%) (8.93%) Irritan contat 0.65%) (0.65%) (0.63%) Nummular 11 05 16 eczema (2.39%) (2.50%) (2.50%) Hyperkeratotic 12 07 19 India cczema 01 08 (1.52%) (0.56%) (1.25%) Air borne 05 0 05 (0.78%) (2.50%) Air borne 05 (1.68%) (2.50%) (2.50%) Sugaran 13 03 16 (2.50%) squara 13 03 16 (2.50%) squara 14 08 (2.50%) (0.94%) squara 11 (1.09%) (1.68%) (0.94%) squara 13 03 16 (2.50%) squara 13 03 03 (0.94%) squara 13 03 03 03			dermatitis	(6.95%)	(13.48%)	(8.78%)
P eczerna (8.47%) (10.11%) (8.33%) Irritant contact (0.66%) (0.63%) Nurmular 11 05 (6 eczema (2.39%) (2.81%) (2.60%) Hyperkeratotic (2.61%) (3.93%) (2.98%) Stasis eczema 07 0 08 it it borne 05 00 05 contact (1.09%) (0.78%) (2.81%) dermatitis 00 6 06 contact (1.09%) (1.68%) (2.50%) squam 0.1 09 56 (1.68%) (2.50%) squam 0.0 6 06 (1.09%) (0.94%) squam 0.1 0.6 06 (1.09%) (0.94%) sticterp strasis 13 01 02 (3.04%) (4.49%) (3.46%) squam 01 0 06 05 (0.94%) (3.46%) Total 18 10			Asteotatic	39	18	57
Irritant contact dermatitis 0.3 0.1 04 Nummular (0.65%) (0.63%) (0.63%) Nummular 11 05 16 eczema (2.39%) (2.81%) (2.50%) Hyperkeratotic 12 07 19 Airb orne 05 (0.56%) (0.28%) Airb orne 05 (0.66%) (1.25%) Airb orne 05 (0.66%) (0.78%) dermatitis 0 0 05 Total 109 56 165 squam 0.3 16 (26.85%) (31.46%) (25.0%) idisorder Idchen planus 05 01 06 05 squam 0.3 05 01 06 03 04 sclerosus et atrophicus 18 10 02 03 04 reactions fixed drug 08 01 04 04 03 05 rotal (2.89%) (3.1			eczema	(8.47%)	(10.11%)	(8.93%)
k dermatitis (0.65%) (0.66%) (0.63%) Nummular 11 05 16 eczema (2.39%) (2.51%) (2.50%) Hyperkeratotic 12 07 19 hand eczema (0.52%) (0.56%) (1.29%) Stasis eczema 07 01 08 (1.52%) (0.56%) (1.25%) (0.78%) Air borne 05 00 05 contact (1.09%) (2.68%) (3.146%) (2.58%) gaguan 00 66 165 (2.83%) (1.68%) (0.94%) Lichen planus 05 0 06 (0.94%) (1.99%) (0.94%) Sclerosus et atorphicus 11 08 01 06 (0.94%) reactions ferued trug 08 01 04 (3.94%) (3.45%) Vitiligo 06 03 09 (1.30%) (1.41%) (1.41%) ry disorder fry <td></td> <td></td> <td>Irritant contact</td> <td>03</td> <td>01</td> <td>04</td>			Irritant contact	03	01	04
Nummular eczema 11 05 16 (2.39%) (2.61%) (2.50%) Hyperkeratotic 12 07 19 hand eczema (2.61%) (3.93%) (2.98%) Stasis eczema 07 01 08 (1.52%) (0.56%) (1.25%) (0.78%) Air borne 05 00 05 contact (1.09%) (3.146%) (25.50%) ous (1.61%) (3.146%) (25.50%) squam 03 16 (3.00%) (2.50%) ous (1.61%) (0.94%) (3.46%) (2.50%) Lichen planus 05 0 06 06 sclerosus et 10 06 06 06 sclerosus et 17041 18 10 28 motions (1.74%) (0.56%) (1.41%) Urticaria 14 08 22 reutions (1.30%) (1.41%) (1.41%) Urticaria 14			dermatitis	(0.65%)	(0.56%	(0.63%)
9 eczema (2.39%) (2.81%) (2.50%) Hyperkeratotic 12 07 19 hand eczema (2.61%) (3.33%) (2.98%) Stasis eczema 07 01 08 (1.52%) (0.56%) (1.25%) (0.78%) Air borne 05 00 05 contact (1.09%) (2.83%) (2.85%) squam (2.83%) (1.68%) (2.50%) squam (2.83%) (1.68%) (2.50%) ous (1.69m) 00 06 06 squam (2.83%) (1.68%) (2.90%) utchen planus 05 01 06 sclerosus et atrophicus (3.30%) (0.94%) (1.41%) reactions Fixed drug 08 01 09 reactions fixed drug 08 01 09 reactions fixed drug 03 03 04 disorder fixed drug 03 0			Nummular	11	05	16
Hyperkeratotic 12 07 19 hand eczema (2.61%) (3.93%) (2.98%) Stasis eczema 07 01 08 (1.52%) (0.56%) (1.28%) Air borne 05 00 05 contact (1.09%) (0.78%) (0.78%) dermatitis 109 56 165 gauam 005 (1.09%) (2.83%) (2.80%) outs disorder Psoriasis 13 03 16 gauam 005 01 06 (0.94%) Lichen planus 05 01 06 (0.30%) (0.94%) Lichen sclerosus et atrophicus 1741 18 10 28 (3.91%) (5.62%) (4.43%) reactions Fixed drug 08 01 09 (1.41%) Urticaria 14 08 (3.45%) (1.41%) Melasma 01 01 02 (0.56%) (0.31%) Airy			eczema	(2.39%)	(2.81%)	(2.50%)
hand eczema (2.61%) (3.93%) (2.98%) Stasis eczema 07 01 08 Air borne (1.52%) (0.56%) (1.25%) Air borne (1.09%) (0.56%) (0.78%) Total 109 56 165 (26.85%) (31.46%) (25.56%) (2.50%) squam 00s (1.69%) (1.68%) (2.50%) uichen planus 05 01 06 06 sclerosus et 10.9%) (0.56%) (0.94%) Lichen 00 06 06 06 sclerosus et 18 10 28 (3.30%) (1.41%) Total 18 10 28 (3.46%) (1.41%) Total 22 9 31 (4.78%) (5.65%) (4.86%) Total 22 9 31 (4.78%) (5.65%) (4.48%) Total 22 9 31 (4.78%) (5.65%) (0.4			Hyperkeratotic	12	07	19
Stasis eczema 07 01 08 Air borne 05 00 05 contact (1.09%) 01 08 dermatitis 109 56 165 7. Papulo- squam Psoriasis 13 03 16 ous Lichen planus 05 01 06 06 ous Lichen planus 05 01 06 06 ous Lichen planus 06 06 06 06 sclerosus et atrophicus 18 10 28 (1.43%) (1.41%) Total 18 0.6562% (1.41%) (1.41%) Urticaria 14 08 22 9 31 Total 22 9 31 (1.41%) (1.41%) Urticaria 14 08 (2.24%) (0.48%) (1.41%) Misorder Measma 01 01 02 (1.24%) (3.45%) Total 10			hand eczema	(2.61%)	(3.93%)	(2.98%)
			Stasis eczema	07	01	08
Air borne contact dermatitis 05 (1.09%) 00 (0.78%) Total 109 56 165 (26.85%) 7. Papulo- squam ous disorder Psoriasis 13 03 16 (2.83%) 1.09 56 165 (26.85%) 01 06 (0.94%) disorder Lichen planus 05 01 06 (0.94%) Lichen planus 00 06 (0.94%) 0.94%) Lichen sclerosus et atrophicus 00 06 (0.94%) 0.94%) Total 18 10 (3.04%) 0.94%) Papulo- sclerosus et atrophicus 0.1 08 (0.94%) 0.141%) Total 18 10 (0.56%) 0.141%) Uritcaria 14 08 (3.04%) 0.86%) 0.141%) Total 22 9 (1.30%) 31 (4.78%) 0.168%) 0.141%) Total 12 9 (1.30%) 0.168%) 0.141%) Melasma 01 01 (0.22%) 0.56%) 0.31%) Jubus Namplocois 03 (0.65%) 0.14%) 0.16				(1.52%)	(0.56%)	(1.25%)
			Air borne	05	00	05
Image: square output is a square output output is a square output is square output is a square output is a square output i			contact	(1.09%)		(0.78%)
Total 109 56 165 squam ous disorder Psoriasis 13 03 16 Ichen planus disorder Ichen planus 05 01 06 Ichen planus disorder 05 01 06 06 Ichen planus 05 01 06 06 Ichen planus 00 06 06 06 Ichen sclerosus et atrophicus 01 08 01 09 reactions Fixed drug eruptions 08 01 09 reactions Fixed drug 08 01 09 rotal 14 08 22 31 (1.74%) (5.05%) (1.41%) 01 01 02 Total 22 9 31 (4.78%) (5.05%) (1.41%) ry Melasma 01 01 02 (0.22%) (0.56%) (0.31%) ford Coll 0.22% (0.56%) (0.31%) (2.66%) <			dermatitis			
Image: square square square disorder Psoriasis 13 03 16 $square disorder Lichen planus 05 01 06 (1.09\%) (0.56%) (0.94%) 0.94%) Lichen planus 00 06 06 (1.09\%) (0.56%) (0.94%) 0.94%) Lichen sclerosus et atrophicus 01 06 (0.94%) Total 18 10 28 (3.91\%) (5.62%) (4.39%) (1.41%) Preactions Fixed drug 08 01 09 (1.74%) (0.56%) (1.41%) (1.41%) Urticaria 14 08 22 (3.04%) (4.49%) (3.45%) (0.56%) Total 22 9 31 ry Melasma 01 01 02 ry Melasma 01 01 02 ry Miloosis 03 03 06 ry Milous 01 $			Total	109	56	165
7. Papulo- squam ous disorder Psoriasis 13 03 16 2.83%) (1.68%) (2.50%) (2.50%) Lichen planus 05 01 06 (1.09%) (0.56%) (0.94%) Lichen 00 06 (0.94%) Total 18 10 28 Total 18 10 09 reactions Fixed drug 08 01 09 eruptions (1.74%) (0.56%) (1.41%) Urticaria 14 08 22 (3.04%) (4.49%) (3.45%) Total 22 9 31 ry (1.30%) (1.68%) (1.41%) disorder Melasma 01 02 ry Melasma 01 02 (0.65%) (0.131%) 7 (2.66%) 10 07 17 (2.12%) (3.93%) (2.66%) 10 02 (0.55%) ((26.85%)	(31.46%)	(25.86%)
squam ous disorder ichen planus Lichen planus (2.83%) (1.68%) (2.50%) Lichen planus disorder 05 01 06 (0.94%) Lichen sclerosus et atrophicus 00 06 06 (0.94%) Total 18 10 28 (3.0%) (0.94%) Total 18 10 28 (3.0%) (1.41%) Verticaria 14 08 21 (1.41%) Urticaria 14 08 22 (3.04%) (4.48%) (3.48%) 9. Pigmenta Vitiligo 06 03 09 (1.41%) ry Melasma 01 01 02 (0.51%) (1.41%) disorder Melasma 01 01 02 (0.56%) (0.31%) ry Helasma 01 01 02 (0.65%) (0.51%) (0.51%) liosorder Pemphigus 03 03 06 (0.65%) (0.56%) (0.51%)	7.	Papulo-	Psoriasis	13	03	16
ous disorder Lichen planus sclerosus et atrophicus 05 (1.09%) 01 (0.56%) 06 (0.94%) Lichen sclerosus et atrophicus 00 06 (3.30%) 00 06 (0.94%) Total 18 (3.91%) 10 28 (3.91%) 28 (5.62%) (4.39%) 8. Drug reactions Fixed drug eruptions 08 (1.74%) 01 09 (0.56%) (1.41%) 174 08 (3.04%) 22 (4.478%) 31 (4.78%) (5.05%) (4.86%) 9. Pigmenta ry disorder Vitiligo 06 (0.65%) 03 (1.68%) 09 (1.41%) Melasma 01 (1.30%) 01 (1.68%) 02 (0.56%) 03.1%) Amylodosis 03 (0.65%) 03 (0.65%) 03 (0.65%) 02 (0.31%) 10 07 (1.08%) 01 (0.22%) 05 (0.56%) 03 (0.31%) 11. Connecti ve tissue disease Systemic lupus (0.22%) 01 (0.56%) 01 (0.56%) 01 (0.56%) 11. Connecti ve tissue erythematosus 0.2 (0.21%) 01 (1.12%) 04 (0.56%) 11. Connecti ve tissue disease Systemic lupus (0.		squam		(2.83%)	(1.68%)	(2.50%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		ous	Lichen planus	05	01	06
Lichen sclerosus et atrophicus 00 06 06 06 Total 18 0 28 (3.91%) (5.62%) (4.39%) 8. Drug reactions Fixed drug eruptions 08 01 09 (1.41%) 10 Urticaria 14 08 22 (3.04%) (4.49%) (3.45%) 7 total 22 9 31 (4.78%) (5.05%) (4.86%) 9. Pigmenta ry Vitiligo 06 03 09 10. Vesicobu llous Melasma 01 01 02 10. Vesicobu llous Pemphigus 01 01 02 10. Vesicobu llous Pemphigus 01 01 02 11. Connecti ve tissue disease Systemic lupus 01 01 02 11. Connecti ve tissue disease Systemic lupus 01 01 02 12. Miscellan eous Vasculitis 03 01 04 </td <td></td> <td>disorder</td> <td>-</td> <td>(1.09%)</td> <td>(0.56%)</td> <td>(0.94%)</td>		disorder	-	(1.09%)	(0.56%)	(0.94%)
$ \begin{array}{ c c c c c c } & sclerosus et atrophicus & (3.30\%) & (0.94\%) \\ \hline retarrophicus & (3.91\%) & (5.62\%) & (4.39\%) \\ \hline Total & 18 & 01 & 09 \\ (3.91\%) & (5.62\%) & (4.49\%) & (1.41\%) \\ \hline urticaria & 14 & 08 & 22 \\ (3.04\%) & (4.49\%) & (3.45\%) & (1.41\%) \\ \hline Urticaria & 14 & 08 & 22 \\ (3.04\%) & (4.49\%) & (3.45\%) & (3.45\%) & (4.86\%) & (1.41\%) & (4.78\%) & (5.05\%) & (4.86\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (1.30\%) & (1.68\%) & (0.94\%) & (1.30\%) & (1.68\%) & (0.94\%) & (1.30\%) & (1.68\%) & (0.94\%) & (1.30\%) & (1.68\%) & (0.94\%) & (1.30\%) & (1.68\%) & (0.94\%) & (1.30\%) & (1.68\%) & (0.94\%) & (0.56\%) & (0.31\%) & (0.65\%) & (0.31\%) & (0.65\%) & (0.31\%) & (0.65\%) & (0.65\%) & (0.31\%) & (0.65\%) & (0.31\%) & (0.65\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.66\%) & (0.94\%) & (0.11\%) & (0.47\%)$			Lichen	00	06	06
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			sclerosus et		(3.30%)	(0.94%)
$\begin{tabular}{ c c c c c c } \hline Total & 18 & 10 & 28 & (3.91\%) & (5.62\%) & (4.39\%) & (4.39\%) & (5.62\%) & (1.41\%) & (1.74\%) & (0.56\%) & (1.41\%) & (1.74\%) & (0.56\%) & (1.41\%) & (1.74\%) & (0.56\%) & (1.41\%) & (1.74\%) & (3.45\%) & (3.45\%) & (4.78\%) & (5.05\%) & (4.86\%) & (4.78\%) & (5.05\%) & (4.86\%) & (4.78\%) & (5.05\%) & (4.86\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (1.30\%) & (1.68\%) & (1.41\%) & (0.22\%) & (0.56\%) & (0.31\%) & (0.22\%) & (0.56\%) & (0.31\%) & (0.65\%) & (0.31\%) & (0.65\%) & (0.56\%) & (0.31\%) & (0.65\%) & (0.31\%) & (0.65\%) & (0.56\%) & (0.31\%) & (0.65\%) & (0.56\%) & (0.31\%) & (1.08\%) & (1.12\%) & (1.09\%) & (1.08\%) & (1.12\%) & (1.09\%) & (1.08\%) & (1.12\%) & (0.56\%) & (0.31\%) & (0.56\%) & (0.78\%) & (0.56\%) & (0.31\%) & (1.08\%) & (1.12\%) & (1.09\%) & (1.12\%) & (1.09\%) & (1.12\%) & (1.09\%) & (1.12\%) & (1.09\%) & (1.12\%) & (0.56\%) & (0.15\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.15\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.57\%) & (0.6\%) & (0.47\%) & (0.6\%) & (0.47\%) & (0.47\%) & (0.6\%) & (0.47\%) & (0.6\%) & (0.47\%) & (0.6\%) & (0.47$			atrophicus		. ,	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Total	18	10	28
8. Drug reactions Fixed drug eruptions 08 01 09 1.74% (0.56%) (1.41%) Urticaria 14 08 22 (3.04%) (4.49%) (3.45%) Total 22 9 31 (4.78%) (5.05%) (4.86%) 9. Pigmenta ry Vitiligo 06 03 09 (1.30%) (1.68%) (1.41%) 0.1 02 (0.22%) (0.56%) (0.31%) 0.3 06 (0.65%) (1.68%) (0.94%) 0.1 02 Amylodosis 03 03 06 0.1 02 (0.56%) (1.68%) (0.94%) 0.1 0.2 0.3 10 07 17 (2.12%) (3.93%) (2.66%) 10 01 01 02 0.1 0.1 05 isorder Pemphigus 01 01 0.56%) (0.18%) 110 Connec				(3.91%)	(5.62%)	(4.39%)
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	8.	Drug	Fixed drug	08	01	09
$\begin{tabular}{ c c c c c c c } \hline Urticaria & 14 & 08 & 22 & (3.04\%) & (4.49\%) & (3.45\%) & (3.45\%) & (7.101 & 22 & 9 & 31 & (4.78\%) & (5.05\%) & (4.86\%) & (1.41\%) & (1.68\%) & (1.41\%) & (1.68\%) & (1.41\%) & (1.68\%) & (1.41\%) & (0.22\%) & (0.56\%) & (0.31\%) & (0.22\%) & (0.56\%) & (0.31\%) & (0.56\%) & (0.31\%) & (0.56\%) & (0.56\%) & (0.31\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.57\%) & (0.56\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.55\%) & (0.56\%) & (0.55\%) & (0.56\%) &$		reactions	eruptions	(1.74%)	(0.56%)	(1.41%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Urticaria	14	08	22
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				(3.04%)	(4.49%)	(3.45%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Total	22	9	31
9. Pigmenta ry disorder Vitiligo 06 03 09 ry Melasma 01 01 02 $disorder$ Melasma 01 0.56%) (0.31%) $Mylodosis$ 03 03 06 (0.56%) (1.68%) (0.94%) $Total$ 10 07 17 (2.12%) (3.93%) (2.66%) (0.31%) $10us$ Pemphigus 01 01 02 $ulgaris$ (0.22%) (0.56%) (0.31%) $ulgaris$ (0.22%) (0.56%) (0.31%) $ulgaris$ (0.22%) (0.56%) (0.31%) $ulgaris$ (0.22%) (0.56%) (0.78%) $pemphigoid$ 05 02 07 (1.08%) (1.12%) (1.09%) (1.12%) $ve tissue$ erythematosus (0.21%) (0.15%) (0.21%) (1.12%) (0.47%) $ve tissue$ Gisease (0.65%) (0.65%)				(4.78%)	(5.05%)	(4.86%)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	9.	Pigmenta	Vitiligo	06	03	09
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		ry	-	(1.30%)	(1.68%)	(1.41%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		disorder	Melasma	01	01	02
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				(0.22%)	(0.56%)	(0.31%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Amylodosis	03	03	06
$ \begin{array}{ c c c c c c } \hline Total & 10 & 07 & 17 \\ (2.12\%) & (3.93\%) & (2.66\%) \\ \hline & (2.95\%) & (0.75\%) & (0.75\%) \\ \hline & (0.22\%) & (0.56\%) & (0.31\%) \\ \hline & 01 & 02 \\ (0.56\%) & (0.56\%) & (0.31\%) \\ \hline & 01 & 05 & (0.56\%) & (0.78\%) \\ \hline & Total & 05 & 02 & 07 \\ (1.08\%) & (1.12\%) & (1.09\%) \\ \hline & Total & 01 & 01 & 02 \\ erythematosus & (0.22\%) & (0.56\%) & (0.31\%) \\ \hline & 01 & 01 & 02 \\ erythematosus & (0.22\%) & (0.56\%) & (0.31\%) \\ \hline & 01 & 01 & 02 \\ erythematosus & (0.22\%) & (0.56\%) & (0.31\%) \\ \hline & 01 & 01 & 02 \\ erythematosus & (0.22\%) & (0.56\%) & (0.15\%) \\ \hline & Total & 01 & 02 & 03 \\ (0.21\%) & (1.12\%) & (0.47\%) \\ \hline & Total & 03 & 01 & 04 \\ eous & (0.65\%) & (0.56\%) & (0.6\%) \\ \hline & & (0.65\%) & (0.56\%) & (0.6\%) \\ \hline & & 10 & 112\% & (1.12\%) & (1.41\%) \\ \hline & Acanthosis & 04 & 06 & 10 \\ erythematosus & (0.87\%) & (3.30\%) & (1.57\%) \\ \hline & Pellagra & 03 & 00 & 03 \\ eous & (0.65\%) & (0.6\%) & (0.47\%) \\ \hline & Total & 14 & 09 & 23 \\ eous & (3.04\%) & (4.98\%) & (7.37\%) \\ \hline \end{array}$				(0.65%)	(1.68%)	(0.94%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Total	10	07	17
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				(2.12%)	(3.93%)	(2.66%)
$ \begin{array}{ c c c c c c c c } \mbox{loss} & \mbox{vulgaris} & \mbox{(0.22\%)} & \mbox{(0.56\%)} & \mbox{(0.31\%)} \\ \mbox{Bullous} & \mbox{04} & \mbox{01} & \mbox{05} \\ \mbox{pemphigoid} & \mbox{(0.87\%)} & \mbox{(0.56\%)} & \mbox{(0.78\%)} \\ \mbox{Total} & \mbox{05} & \mbox{(0.10\%)} & \mbox{(1.12\%)} & \mbox{(1.09\%)} \\ \mbox{Total} & \mbox{05} & \mbox{(0.22\%)} & \mbox{(0.12\%)} & \mbox{(0.31\%)} \\ \mbox{ve tissue} & \mbox{erythematosus} & \mbox{(0.22\%)} & \mbox{(0.56\%)} & \mbox{(0.31\%)} \\ \mbox{ve tissue} & \mbox{erythematosus} & \mbox{(0.22\%)} & \mbox{(0.56\%)} & \mbox{(0.31\%)} \\ \mbox{ve tissue} & \mbox{erythematosus} & \mbox{(0.22\%)} & \mbox{(0.56\%)} & \mbox{(0.31\%)} \\ \mbox{disease} & \mbox{Systemic} & \mbox{00} & \mbox{01} & \$	10.	Vesicobu	Pemphigus	01	01	02
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		llous	vulgaris	(0.22%)	(0.56%)	(0.31%)
$ \begin{array}{ c c c c c c } \hline pemphigoid & (0.87\%) & (0.56\%) & (0.78\%) \\ \hline Total & 05 & 02 & 07 \\ (1.08\%) & (1.12\%) & (1.09\%) \\ \hline \end{tabular} \\ \hline \end{tabular} \\ \e$		disorder	Bullous	04	01	05
$ \begin{array}{ c c c c c } \hline Total & 05 & 02 & 07 \\ (1.08\%) & (1.12\%) & (1.09\%) \\ \hline \\ 11. Connecti ve tissue disease & crythematosus & (0.22\%) & (0.56\%) & (0.31\%) \\ \hline \\ sclerosis & 00 & 01 & 01 \\ sclerosis & 00 & 01 & 01 \\ sclerosis & 00 & 01 & 01 \\ (0.56\%) & (0.15\%) \\ \hline \\ Total & 01 & 02 & 03 \\ (0.21\%) & (1.12\%) & (0.47\%) \\ \hline \\ 12. Miscellan eous & Vasculitis & 03 & 01 & 04 \\ eous & (0.65\%) & (0.56\%) & (0.6\%) \\ \hline \\ Keloid & 07 & 02 & 09 \\ (1.52\%) & (1.12\%) & (1.41\%) \\ Acanthosis & 04 & 06 & 10 \\ nigricans & (0.87\%) & (3.30\%) & (1.57\%) \\ \hline \\ Pellagra & 03 & 00 & 03 \\ (0.65\%) & Total & 14 & 09 & 23 \\ (3.04\%) & (4.98\%) & (7.37\%) \\ \hline \end{array} $			pemphigoid	(0.87%)	(0.56%)	(0.78%)
$ \begin{array}{ c c c c c c } \hline & (1.08\%) & (1.12\%) & (1.09\%) \\ \hline & (1.12\%) & (1.09\%) \\ \hline & (1.12\%) & (1.09\%) \\ \hline & (1.12\%) & (0.16\%) & (0.11\%) \\ \hline & (0.11\%) & (0.11\%) & (0.11\%) & (0.11\%) \\ \hline & (0.11\%) & (0.11\%) & (0.11\%) & (0.11\%) \\ \hline & (0.11\%) & (0.11\%) & (0.11\%) & (0.11\%) & (0.11\%) \\ \hline & (0.11\%) & (0.1$			Total	05	02	07
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				(1.08%)	(1.12%)	(1.09%)
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	11.	Connecti	Systemic lupus	01	01	02
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		ve tissue	erythematosus	(0.22%)	(0.56%)	(0.31%)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		disease	Systemic	00	01	01
Total 01 02 03 (0.21%) (1.12%) (0.47%) 12. Miscellan eous Vasculitis 03 01 04 (0.65%) (0.56%) (0.6%) (0.6%) Keloid 07 02 09 (1.52%) (1.12%) (1.41%) Acanthosis 04 06 10 nigricans (0.87%) (3.30%) (1.57%) Pellagra 03 00 03 (0.65%) (0.47%) 70tal 14			sclerosis		(0.56%)	(0.15%)
Image: Non-structure (0.21%) (1.12%) (0.47%) 12. Miscellan eous Vasculitis 03 01 04 eous (0.65%) (0.56%) (0.6%) Keloid 07 02 09 (1.52%) (1.12%) (1.41%) Acanthosis 04 06 10 nigricans (0.87%) (3.30%) (1.57%) Pellagra 03 00 03 (0.65%) Total 14 09 23			Total	01	02	03
$\begin{array}{c c c c c c c c c c c c c c c c c c c $				(0.21%)	(1.12%)	(0.47%)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	12.	Miscellan	Vasculitis	03	01	04
Keloid 07 (1.52%) 02 (1.12%) 09 (1.41%) Acanthosis nigricans 04 (0.87%) 06 (3.30%) 10 (1.57%) Pellagra 03 (0.65%) 00 (0.47%) 03 (0.47%) Total 14 (3.04%) 09 (4.98%) 23 (7.37%)		eous		(0.65%)	(0.56%)	(0.6%)
(1.52%) (1.12%) (1.41%) Acanthosis 04 06 10 nigricans (0.87%) (3.30%) (1.57%) Pellagra 03 00 03 (0.65%) (0.47%) (0.47%) Total 14 09 23			Keloid	07	02	09
Acanthosis nigricans 04 (0.87%) 06 (3.30%) 10 (1.57%) Pellagra 03 (0.65%) 00 (0.47%) 03 (0.47%) Total 14 (3.04%) 09 (4.98%) 23 (7.37%)				(1.52%)	(1.12%)	(1.41%)
nigricans (0.87%) (3.30%) (1.57%) Pellagra 03 00 03 (0.65%) (0.47%) (0.47%) Total 14 09 23 (3.04%) (4.98%) (7.37%)			Acanthosis	04	06	10
Pellagra 03 (0.65%) 00 (0.47%) Total 14 (3.04%) 09 (4.98%) 23 (7.37%)			nigricans	(0.87%)	(3.30%)	(1.57%)
(0.65%) (0.47%) Total 14 09 23 (3.04%) (4.98%) (7.37%)			Pellagra	03	00	03
Total 14 09 23 (3.04%) (4.98%) (7.37%)				(0.65%)		(0.47%)
(3.04%) (4.98%) (7.37%)			Total	14	09	23
				(3.04%)	(4.98%)	(7.37%)

Table 3 shows that most common symptom seen in participants was generalized pruritus observed in 73% males and 66% females. Fungal infection was seen in 28.21% patients. Bacterial infection was marginally lower (26%) than fungal infection among participants and viral infections were observed in 12.38% of patients, out of which Herpes zoster

PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 11 | Issue - 10 |October - 2022 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

was the most common viral infection comprising of 6.9% of total patients. Parasitic infestations were seen in about 6% of participants. Eczematous conditions were seen in almost 26% of participants among which Asteatotic eczema and Allergic contact dermatitis included approximately 9% of participants. Papulo-squamous disorder, Cutaneous adverse drug reactions, Pigmentary disorders, Vesicobullous disorder and Autoimmune Connective tissue disorder were less (<5%) prevalent in participants with autoimmune connective tissue disorders being the least common (0.21%).



Figure 1: Morphea Over Waist Region In A 62 Year Old Female



Figure 2: Drug Induced Erythema Multiforme In A 67 Year Old Male



Figure 3: Multiple Tense Bullae In A 78 Years Old Male Patient Diagnosed As Bullous Pemphigoid www.worldwidejournals.com
 Table 4: Distribution Of Associated Systemic Diseases

 (co-morbidities) Among Participants

Systemic disease	No. of cases	Percentage
Hypertension	86	13.48%
Diabetes mellitus	78	12.23%
Ischemic heart disease	31	4.86%
Asthma/ COPD	18	2.83%
Hypothyroidism	23	3.61%
Renal disease	17	2.66%
Cerebrovascular accident	02	0.32%
Anemia	40	6.23%
Tuberculosis	03	0.48%
Malignancy	08	1.28%

Table 4 indicates that Hypertension and Diabetes were most commonly seen co-morbidities among participants with prevalence being about 13% and 12% respectively.3rd& 4th most common associated co-morbidities were Ischemic heart diseases (5%) and Hypothyroidism (4%) respectively while Renal diseases, Cardiovascular accident, Anemia, Tuberculosis and Malignancy were least common (<2%) comorbidities found among participants.

Table 5: Pattern Of Cutaneous Tumours In Geriatric Population

Tumor Type	Sub type	No. of	Percentage
		cases	
Benign	DPN	248	39%
	Cherry angioma	434	68%
	Seborrheic keratosis	123	19%
	Acrochordon	114	17%
Malignant	Squamous cell carcinoma	2	0.31%
	Basal cell carcinoma	4	0.62%

As shown in table 4, among cutaneous tumours, benign tumours were commonly seen among participants, most common being cherry Angioma seen in 68% patients, while malignant tumours were seen very rarely (<1%) among participants.



Figure 4: Squamous Cell Carcinoma Over Post Burn Scar In An 83Year Old Female

DISCUSSION:

Most commonly affected age group in our study was 60-69 yrs (58.5%). In the studies conducted by Agarwal R et al ^[7]. Kumari J et al ^[8]. Kandwal M et al ^[9] and Meena P et al ^[10] also reported 60–69 years age group as most commonly affected group with

PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 11 | Issue - 10 |October - 2022 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

their proportion being 68.4%, 52.2%, 56.4% and 61% respectively which was comparable to the findings of our study.

In present study, male participants were 72% of all participants while the proportion of male participants were 58.4%, 60%, 66.6% and 59% in the studies conducted by Agarwal R et al ^[7]. Kumari J et al ^[8]. Kandwal M et al ^[9] and Meena P et al ^[10] respectively. These findings were comparable to all compared studies of North and North-east India.

Most common senile physiological changes were canities (91%) and wrinkles (86%) in our study.Wrinkles (97.8%) and cherry angioma (91.8%) were two most prevalent senile skin changes in the study by Agarwal R et al ^[7] while study by Kumari J et al ^[8] showed xerosis and wrinkles as two commonest physiological changes. Xerosis (63%) and wrinkling (24%) were found as most common physiological cutaneous manifestation in the study by Meena P et al ^[10]. 'Wrinkles' came out to be a most common finding among all these studies.

Most common skin symptom seen in participants was generalized pruritus (73%) in our study in comparison to 56% in the study by Agarwal et al ^[7]. The prevalence of fungal infection was 25%, 22-30%, 24% and 17% in present study, studies done by Agarwal et al ^[7]. Kandwal et al ^[9] and Meena P et al ^[10] respectively which were quite similar in above mentioned studies ranging from 17-30%, while the prevalence of the same was quite lower (11%) in study conducted by Kumari J et al ^[9]

The prevalence of viral infection in our study (12%) was comparable to the study done by Meena P^[10] et al (15%), while it was lower in the studies done by Agarwal R^[7] et al (5%), Kumari J^[8] et al (5.5%) and Kandwal M^[9] et al (2%).

On comparing the prevalence of bacterial infection in participants, it was 21%, 29%, 10.5%, 1% and 10% in present study, studies done by Agarwal R et al ^[7]. Kumari J et al, Kandwal et al ^[8] and Meena P et al ^[10] respectively which shows very wide variations (1-29%) in different parts of North and North-east India. Such wide variation requires a separate study to know the reason behind.

Parasitic infestations were seen in about 6% of participants in our study which also shares more or less similar picture with the studies by Kumari J et al^[8] and Kandwal et al^[9] (with prevalence 3.3% and 11% respectively).

Eczema was seen in 26% of participants in our study while the same had prevalence of 30%, 23% and 26% in the studies done by Kumari J et al ^[8]. Kandwal et al ^[9] and Meena P et al ^[10] respectively. This shows that the eczematous conditions were uniformly common among different parts of North and Northeast India.

Drug reactions (4.86%), Pigmentary disorders (2.66%), Vesicobullous disorder (1.09%) and Connective tissue disorder (0.47%) were seen in fewer participants with connective tissue disorders being the least common (0.47%) in our study. These findings showed almost similar prevalence in the study done by Agarwal et al ^[7] (drug reactions 0.4-1%, pigmentary disorders 0.4%, Vesicobullous disorder 0.5-1%, Connective tissue disorder 0.3-1%) also.

Hypertension, Diabetes & Ischemic heart diseases were the most commonly seen co-morbidities among participants with prevalence being 13.48%, 12.23% and 4.86% respectively in our study which shows quite similar pattern of co-morbidities in the study by Meena P et al ^[10] showing Diabetes (38%), hypertension (19%) and Coronary Artery Diseases (19%) as the 3 most commonly seen co-morbidities with contrasting higher prevalence of the same in this study^[10].

Among cutaneous tumors, benign tumors were seen commonly out of which cherry angioma were the most common tumour seen in 68% of participants in our study. Other benign tumors included DPN (38.9%), Seborrheic keratosis (19.3%), Achrocordon (17.8%). Benign tumors were present in 2-22% and 0.8% of participants in studies of Kumari J et al ^[8] and Kandwal et al ^[9] respectively which again shows different prevalence in different parts of North and Northeast India. Fortunately malignant tumours were seen very rarely (<1%) in our study including 4 cases (0.62%) of Basal cell carcinoma and 2 cases (0.31%) of squamous cell carcinoma. The prevalence of the malignant skin tumors was comparable (0.8%) in study done by Kandwal et al ^[9].

CONCLUSION:

As per the saying "All that stands, decays", our skin also bears the changes due to internal as well as external environmental stressors. Physiological changes like Xerosis or Senile pruritus (either was seen in $3/4^{\text{th}}$ of participants) alone can lead to significant distress to the elderly patients. In addition, multiple pathologies are specifically identified in geriatric population. By integrating this knowledge in health care facilities including Primary health centres, we can improve the quality of life of older age population.

REFERENCES:

- Park, K. 2017. Park's textbook of Preventive and Social Medicine (24th edition). Jabalpur: M/s Banarasidas Bhanot. Page: 521
- 2. https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=IN last accessed 27.09.2022
- Beauregard S, Gilchrest B. A survey of skin problems and skin care regimens in the elderly. Arch Dermatol . 1987;123(12):1638–43. doi:10.1001/archderm. 123.12.1638
- Gupta P, Khan AM. Preventive Geriatrics. In: Gupta P (eds.) Textbook of Community Medicine. New Delhi: CBS Publishers; 2016, p.718.
- Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin. Am J ClinDermatol 2009;10:73-86.
 Waller JM, Maibach HI. Age and skin structure and function, a quantitative
- Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I):Blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005;11:221-35.
- Agarwal R, Sharma L, Chopra A, Mitra D, Saraswat N. A cross-sectional observational study of geriatric dermatoses in a Tertiary Care Hospital of Northern India. Indian Dermatol Online J 2019;10:524-9
- Kumari J, Gupta B. A clinical study of pattern of geriatric dermatoses. Indian J Clin Exp Dermatol 2019;5(4):288-294.
- Kandwal M, Jindal R, Chauhan P, Roy S. Skin diseases in geriatrics and their effect on the quality of life: A hospital-based observational study. J Family Med Prim Care 2020;9:1453-8.
- Meena P, Soni B. A clinical study of pattern of geriatric dermatosis in tertiary care hospital of Rajasthan. IP Indian J Clin Exp Dermatol 2021;7(2):148-152.